Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via Google Scholar Articles by Kleinman, I. Articles by Schachter, D. Search for Related Content PubMed Citation Articles by Kleinman, I. Articles by Schachter, D. Informed Consent Conventional Neuroleptics

Obtaining Informed Consent of Patients at Risk of Neuroleptic Malignant Syndrome

Thirty psychiatrists completed a mailed questionnaire about their attitudes toward obtaining informed consent and about the frequency with which they obtained it from patients taking neuroleptic medications who were at risk of tardive dyskinesia, a relatively common but nonfatal side effect, and neuroleptic malignant syndrome (NMS), an uncommon but potentially fatal side effect. Only one psychiatrist reported always or almost always informing patients about the risk of NMS. Psychiatrists were significantly less likely to inform patients about the risk of NMS than the risk of tardive dyskinesia. Psychiatrists may not be aware of the risk of NMS and may not know what information to provide to patients.

Get information about faster international access.

Privacy Policy

Copyright © 2000 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us